511 results about "Rat model" patented technology

The invention provides a method for establishing an obese rat animal model based on a CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout technology. The method comprises the following steps: (1) establishing an Lep/Lepr gene knockout rat model; (2) carrying out the authentication and related analysis on the obese rat animal model; (3) evaluating the energy metabolism and the body fat rate of the obese rat animal model. According to the method, a CRISPR/Cas system is used for respectively or simultaneously knocking out Lep and LepR genes so as to obtain the rat model modified by a corresponding target gene, so that the understanding of gene regulation in the obesity morbidity process can be deepened, and the high-level animal model can be provided for the translational medicine and the new medicine research and development.

The application of Magnolia officinalis preparation for the production of medicaments for treating diabetes and obesity belongs to the field of medicinal application. The Magnolia officinalis preparation is extracted from Magnolia officinalis by soaking in ethanol with magnolol and honokiol as main ingredients. The preparation has effects of in-vitro inhibiting the activity of protein-tyrosine phosphatase 1B (PTP1B) and reducing blood sugar level in rat model of type 2 diabetes. The preparation can be made into powder, pill, capsule, tablet, oral liquid and injection. It can be used for treating diabetes, obesity, and diseases related to PTP1B.

This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.

The invention relates to the related ingredient combination with the function of relaxing vessels in traditional Chinese medicine for reducing blood pressure which is commonly used clinically. The invention utilizes modern traditional Chinese medicine theory and provides a related ingredient combination with definite ingredient, controllable quality and precise curative effect by animal model tests for reducing blood pressure. The related ingredient combination can be used for relaxing vessels, treating hypertension and improving hypertension complication. The commonly used traditional Chinese medicine relates to eucommia ulmoides, rhizoma gastrodiae, rhizoma chuanxiong, salviae miltiorrhizae, Astragalus mongholicus, root of kudzu vine, uncaria, radix stephaniae tetrandrae, red flower, radix scutellariae, selfheal, semen cassiae, dogbane leaf, hawthorn, radix achyranthis bidentatae, sophora flower, pseudo-ginseng, motherwort, chrysanthemum, lotus plumule, evodia, cape jasmine fruit, epimedium and caltrop which are included in Chinese Pharmacopoeia (2010 edition). The related ingredients are active ingredients which are extracted from single traditional Chinese medicine. Each traditional Chinese medicine provides one or several active ingredients. The combination study comprises the following steps of combining 2-6 active ingredients with different mechanisms in proportion, screening by utilizing rat thoracic aorta vascular rings and spontaneous hypertension rat models and determining the optimum combination proportion.

The invention relates to a medicine for externally treating burn and scald, which is an ointment prepared from slough tissue of cultured second generation giant salamanders and subsequent generations thereof during growth period, radix glycyrrhizae, borneol, sinkiang arnebia root and sanguisorba officinalis. The inventive ointment is prepared from the radix glycyrrhizae extract, sinkiang arnebia root extract, sanguisorba officinalis extract and nanometer powder of giant salamander slough tissue that are obtained by modern biotechnology. The preparation method og the medicine comprises the steps of mixing according to a certain proportion, adding borneol and matrix that is made of Vaseline, vegetable oil, beeswax and anhydrous lanolin, homogenizing, and making into the ointment. The inventive medicine has the advantages of good therapeutic effect, quick action, good analgesic effect, short treatment course, no scar left, and no any toxic and side effects. Burn and scald rat model experiments prove that the inventive medicine shortens the healing time of the superficial second degree, the deep second degree and the third degree burns, there is no scar left on wound surface after healing for the superficial second degree and the deep second degree burns, and there is less scar left on wound surface after healing the third degree burn, with no need of skin grafting. The inventive medicine has better therapeutic effect than the prior medicines for treating burn and scald, and has very wide application prospect.

The invention relates to a method for detecting, screening and identifying metabolism biomarkers, in particular to a method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers. In order to solve the problem that in the prior art kidney-yang deficiency metabolism biomarkers cannot be determined, the method for detecting, screening and identifying kidney-yang deficiency metabolism biomarkers comprises the steps that a kidney-yang deficiency rat model is copied, a kidney-yang deficiency rat model is evaluated, a rat urine or blood QC sample is obtained through preparation; urine endogenous metabolites and blood endogenous metabolites are obtained; 33 urine biomarkers and 17 blood biomarkers are obtained through determination and identification of a rat urine metabolism counter track variation trend PCA score chat. The method is applied to the field of metabolism biomarker detection, screening and identification.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The invention aims to establish a rat model concerning pharmacodynamic screening, pharmological study and efficacy evaluation of a traditional Chinese medicine for treating concomitant hyperlipidemia and hypertension. On the basis of a hypertension rat model, model set rats are fed with high fat diet each day continuously for 2-6 weeks so as to create a hypertension complicated by hyperlipidemia model. The characteristic indicators of the model are mainly that the total cholesterol and triglyceride as well as low density lipoprotein cholesterin can be increased, and high-density lipoprotein cholesterol can be decreased while the blood pressure is increased.

Huntington's Disease (HD) is an autosomal-dominant inherited progressive neurodegenerative disease from the group of CAG repeat/polyglutamine diseases and is characterized by a triad of psychiatric alterations, dementia and motor dysfunction. On a sub-cellular level, a mutation with extended CAG tri-nucleotide repeats has been identified as the cause of HD. The therapeutic effects of certain substances can be tested on neurotoxically-induced or transgenic animal models with expanded CAG-repeats. In the present invention, transgenic rats were generated and characterized for human HD. Said rat model for human HD and other diseases of the CNS carries 51 CAG repeats under the control of a rat promoter and has a slow progressive neurological phenotype, closely reflecting human HD syndrome. The comparability of the rat model in relation to human HD is characterized by neuropathological, neuroradiological and neurochemical modifications accompanied by typical behavioral symptoms.

The invention discloses a traditional Chinese medicine formulation for curing senile dementia and a preparation method thereof. The traditional Chinese medicine formulation is made of ginseng, milk veteh, epimedium, fumitory, rhizoma gastrodiae, angelica, radid polygoni multflori preparata, sealwort and grassleaf sweelflag rhizome which are performed by an ethanol extracting technology and a poach technology. The traditional Chinese medicine formulation is ground by the theory of traditional Chinese medicine and adopts a scientific theory and an advanced technology to develop the traditional Chinese medicine formulation with good curative effect and fewer side effects and being used for curing the senile dementia. The experimental research shows that the traditional Chinese medicine formulation can improve the learning memory ability of an AD rat model. Meanwhile, the traditional Chinese medicine formulation can improve the antifatigue and anti-stress ability of an organism and has good curative effect on the kidney empty. In addition, the invention also provides an optimized preparation method suitable for the industrial production.

The invention discloses a stem cell preparation for treating cirrhosis, which is prepared from stem cells from human umbilical cord placenta, normal saline containing seralbumin with concentration by volume being 0.5-5%, and low-molecular-weight heparin sodium with concentration being 50-701U/ml. When the stem cell preparation is transfused into a rat model with cirrhosis through a caudal vein, the effective dose of the stem cell preparation is 5*106 cells each time; and the effective dose of the stem cell preparation is 0.5-5*106 cells/ kg each time when the stem cell preparation is transfused into a patient with cirrhosis through a peripheral vein. After applied to rats with cirrhosis and patients with cirrhosis, the stem cell preparation can obviously improve the survival rate of the rats with cirrhosis and the patients with cirrhosis, retard and invert a cirrhosis process, improve a whole state and a liver function state, and promote pathological recovery of liver, thereby developing a new way to cell therapy for treating cirrhosis.

The invention provides a preparation for inula wissmannian extracts and an application of the extracts in preparation of an anti-inflammatory medicine. The extracts are germacrane sesquiterpene lactone inula wissmannian lactones A, B, C, D and E and inula cappa lactone with the following chemical structural formulas and absolute configurations shown in the specification, wherein the inula wissmannian lactones A, B, C, D and E and the inula cappa lactone generate an inhibition effect on the NO of the RAW264.7 macrophage induced by LPS (lipopolysaccharide); and in an xylene-induced ear swelling mouse model and a Freund complete adjuvant arthritis rat model, the inula wissmannian lactones A, B, C, D and E and the inula cappa lactone are found to be able to obviously inhibit the ear swelling and foot swelling of experimental animals, and the result indicates that the inula wissmannian lactones A, B, C, D and E and the inula cappa lactone are good in anti-inflammatory activity, capable of being used for preparing an anti-inflammatory medicine, and great in application value. The invention provides an extraction and separation method for the inula wissmannian lactones A, B, C, D and E and the inula cappa lactone.

The invention relates to an experimental animal feeding cabin, which is the big and small mice feeding cabin for simulating the symptom of intermittent anaerobic respiration of animal. One side of hypoxia feeding cabin is further connected with a buffering cabin formed from a closed cabin body and a feeding cage track such that the feeding cabin loading the big mouse is timed to stay between the hypoxia feeding cabin and the outside along the feeding cage track so as to simulate the big mouse model of SAS by the long-period intermittent breathing hypoxia gas. There is no need to timely and frequently discharge the nitrogen in the hypoxia feeding cabin, thus, the consumption quantity of the nitrogen is greatly reduced and the experiment cost is reduced by a wide margin.

The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.

The invention relates to a system for determining functions of lower lib nerves and muscles of a rat. The system consists of a fixing device, a sensing device and a data processing device, the fixing device is connected with the sensing device via an electrical stimulation line and an output line, the sensing device is connected with the data processing device via a lead, the data processing device transmits nerve stimulation signals to the fixing device via the sensing device, the fixing device transmits received mechanical muscle force signals into the sensing device, the mechanical muscle force signals are converted and processed into electric signals via the sensing device, and the electric signals are transmitted into the data processing device, so that muscle force data are obtained. Compared with the prior art, the system provides a novel and reliable experimental platform, can digitally, quantitatively and dynamically monitor a single group of muscle force of a rat model, and accurately measures change of the muscle force of a research object at different time points.

The invention relates to a pulsatile delivery sustained-release tablet for treating diabetes mellitus and a preparation method thereof. The active components of the pulsatile delivery sustained-release tablet liraglutide, exenatide acetate or pramlintide acetate are respectively combined with insulin, and drugs are released according to a preset time. According to the pulsatile delivery sustained-release tablet, a polymer material is adopted as a coating film, the active components are combined with a swelling coating to serve as a tablet core, and medical auxiliaries are adopted. The dissolution percentage of the composition is further investigated, and an SD (sprague-dawley) diabetes rat model is used as a studying object to detect the fasting blood-glucose, 2hplasmaglucose, number of hypoglycemia times, dawn phenomenon indexes of the rat model, and the treatment effects are investigated.

The invention belongs to the field of traditional Chinese medicines, relates to a compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof, and in particular relates to a compound traditional Chinese medicinal component preparation comprising geniposide and chlorogenic acid and application thereof. The compound preparation is prepared from geniposide and chlorogenic acid, and can be processed into clinical common preparations by a conventional method, including granules, tablets, capsules and other oral solid preparations. Animal experiments indicate that the compound preparation can remarkably reduce the content of triglyceride of liver tissues of a rat model, and reduce the degeneration degree of liver fat and liver damage degree. The effects of the compound preparation are superior to those of single component. The compound preparation can be used for improving the effect of resisting alcoholic fatty liver, effectively preventing development of non-alcoholic fatty liver, and can be used for treating and preventing non-alcoholic fatty liver, chronic liver damage and other symptoms.

The invention discloses an application of baicalin in preparation of a medicine for treating polycystic ovarian syndrome. As shown in an in vivo experiment, the baicalin has obvious treatment effect on a polycystic ovarian syndrome rat model and can greatly reduce the high androgen level of the rat model, promote follicle maturity and induce ovulation; as shown in an in vitro experiment, the baicalin can inhibit the expression of androgen of a polycystic ovarian syndrome cell model. More importantly, the baicalin has small side effect and incomparable security while having no liver and kidney toxicity. Therefore, the baicalin can be used for preparing the medicine for treating polycystic ovarian syndrome and has a brilliant prospect.

The invention relates to a method for establishing a CYP2D1 gene knockout rat model, and belongs to the technical field of transgenosis. The method comprises the steps of firstly determining a target point of a to-be-knocked gene and designing and synthesizing a primer sequence of the gene; inserting the primer sequence into a Cas9-gRNA-Bsal carrier subjected to enzyme digestion and performing amplification to obtain a target point sgRNA with a T7 promoter sequence; after in vitro transcription and purification, performing activity detection; micro-injecting active sgRNA and Cas9 RNA into a rat single-cell embryo to obtain a Founder rat; and after screening out a CYP2D1 gene knockout rat heterozygote, performing mating to obtain a homozygote individual, namely, a CYP2D1 gene knockout rat. The invention provides a preparation method replacing a mouse model with a P450 gene knockout rat model, so that a gene knockout technology is really fused in non-clinical safety evaluation of drugs and early toxicity of candidate drugs can be discovered.

The invention discloses compounds with thrombolytic activities, preparation methods thereof and applications of the compounds as thrombolytic agents. The compounds disclosed by the invention are prepared by coupling or conjugating the 2 nitrogen of cyclized dopa respectively with H-Ala-Arg-Pro-Ala-Lys-OH, H-Pro-Ala-Lys-OH, H-Arg-Pro-Ala-Lys-OH, H-Gly-Arg-Pro-Ala-Lys-OH or H-Gln-Arg-Pro-Ala-Lys-OH. The thrombolytic activities of the compounds disclosed by the invention are evaluated by a rat model with carotid artery and jugular vein bypass catheter thrombosis, and shown by experimental results, the compounds disclosed by the invention have excellent thrombolytic activities and can be applied as thrombolytic agents clinically. The therapeutic actions of the compounds disclosed by the invention on cerebral infarction are further evaluated by a rat model with cerebral thrombosis, and shown by experimental results, the compounds disclosed by the invention all have excellent protective actions on brain tissues and can be applied as cerebral thrombolytic agents clinically.

The invention discloses application of ethyl asterrate in preparation of an anti-alzheimer medicine, and in particular relates to application of diphenyl ether compound ethyl asterrate shown in the structural formula (I) in inhibition of the activity of acetylcholine esterase and preparation of an anti-alzheimer medicine. Experiments prove that the ethyl asterrate can remarkably inhibit the activity of acetylcholine esterase, can remarkably improve the memory and space exploration capability of an alzheimer rat model caused by D-galactose and AlCl3, can be applied to preparation of the anti-alzheimer medicine, and indicates an excellent market application prospect.